Combined Peritumoral and Subareolar Injection of Blue Dye Improves Sentinel Lymph Node Localization Rates / 한국유방암학회지

PURPOSE: The sentinel lymph node (SLN) biopsy was recently introduced into the treatment of early breast cancer. However, there have been varying degrees of success in identifying the SLNs. Lymphatic mapping in breast cancer performed solely by intraparenchymal injection of blue dye remains an accepted method of identifying SLNs, largely because of its simplicity. This article describes the technical aspect and improved results of combined peritumoral and subareolar injection of isosulfan blue dye. METHODS: From Jan. 2000 to Jul. 2000, 55 patients with breast cancer (size<5 cm and clinically negative axillary nodes) were enrolled for SLN biopsy by peritumoral and subareolar injection of 1% isosulfan blue dye. And all patients underwent a complete axillary dissection. RESULTS: The identification rate of SLN was 96.4% (in 53 of 55 patients). Of these 53 patients, 11 patients (20.8%) had positive SLNs and 42 patients had negative SLNs. In 42 patients with negative SLNs, one patients was found to have disease on complete dissection, for a false-negative rate of 8.3% (1/12). Conclusion: Compared with other series of blue dye- directed lymphatic mapping, the present study of peritumoral plus subareolar plexus dye-only injection demonstrates a high SLNs localization rate and rapid learning curve. On the basis of these results, it is expected that subareolar lymphatic plexus is the central route to sentinel lymph nodes and the optimal way to perform dye-only lymphatic mapping of the breast.

Combined Peritumoral and Subareolar Injection of Blue Dye Improves Sentinel Lymph Node Localization Rates

PURPOSE: The sentinel lymph node (SLN) biopsy was recently introduced into the treatment of early breast cancer. However, there have been varying degrees of success in identifying the SLNs. Lymphatic mapping in breast cancer performed solely by intraparenchymal injection of blue dye remains an accepted method of identifying SLNs, largely because of its simplicity. This article describes the technical aspect and improved results of combined peritumoral and subareolar injection of isosulfan blue dye. METHODS: From Jan. 2000 to Jul. 2000, 55 patients with breast cancer (size<5 cm and clinically negative axillary nodes) were enrolled for SLN biopsy by peritumoral and subareolar injection of 1% isosulfan blue dye. And all patients underwent a complete axillary dissection. RESULTS: The identification rate of SLN was 96.4% (in 53 of 55 patients). Of these 53 patients, 11 patients (20.8%) had positive SLNs and 42 patients had negative SLNs. In 42 patients with negative SLNs, one patients was found to have disease on complete dissection, for a false-negative rate of 8.3% (1/12). CONCLUSION: Compared with other series of blue dye- directed lymphatic mapping, the present study of peritumoral plus subareolar plexus dye-only injection demonstrates a high SLNs localization rate and rapid learning curve. On the basis of these results, it is expected that subareolar lymphatic plexus is the central route to sentinel lymph nodes and the optimal way to perform dye-only lymphatic mapping of the breast.

Correlation between Tumor Response to Neoadjuvant Chemotherapy and Patient Outcome in Breast Cancer

PURPOSE: Neoadjuvant chemotherapy is being used increasingly in the treatment of patients with large or locally advanced breast cancer with the aims of downstaging and eliminating micrometastasis. We report a correlation between tumor response to preoperative primary chemotherapy and patient outcome in a series of 73 consecutive patients with breast cancer. METHODS: From Feb. 1991 to Oct. 1998, 73 patients with breast cancer (tumor size>3 cm or clinically axillary node positive) were treated with multimodality therapy, including a sandwich type of chemotherapy, comprised of 3 preoperative cycles and 3 postoperative 3 cycles of FEC or MMM. The median follow-up period was 53 months. RESULTS: The overall objective clinical response rate (complete & partial response) of the primary tumor to chemotherapy was 75.5% (standard UICC criteria). The pathologic complete response rate was 9.6%. The overall 5-year survival rate was 86.8%, and the overall 5-year disease free survival rate was 82.6%. The response rate to chemotherapy declined with increasing tumor size, but there was no relationship between the clinical response to chemotherapy and menopausal status, chemotherapeutic regimen, or histopathologic type. A breast-conserving operation could be done in 64.4% of the patients as a result of a decrease in the tumor size. CONCLUSION: Neoadjuvant chemotherapy allows a breast-conserving operation to be performed more frequently in cases of large or locally advanced breast cancer. The responses to neoadjuvant chemotherapy is a powerful prognostic factor for the overall survival and the disease free survival in breast cancer patients.